Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06190678 · ClinicalTrials.gov registry record · Phase 1
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT06190678 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 16 participants.
The verdict
NCT06190678, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into the bloodstream and how long it takes the body to eliminate it in participants with impaired kidney function and healthy participants. The side effects and tolerability of pirtobrutinib will also be evaluated. Participation could last around 46 days.
Interventions
- DRUG Pirtobrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2021-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06190678
The ClinicalTrials.gov registry entry for NCT06190678 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pirtobrutinib is the first listed.
NCT06190678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06190678 about?
NCT06190678 is a clinical study titled "Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants". The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into the bloodstream and how long it takes the body to eliminate it in participants with impaired kidney function and healthy participants. The side effects and tolerability of pirtobrutinib will also be evaluated...
What is the current status of trial NCT06190678?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-02-01. Estimated completion is 2021-06-04.
What interventions are being tested in trial NCT06190678?
The interventions under investigation include: Pirtobrutinib (DRUG).
Who is sponsoring clinical trial NCT06190678?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.